PharmaGraphX

Log in Get Started

Ribociclib

Kisqali

Uncategorized

Standard

Half-life

33 hours

Protein Binding

70%

Metabolized By

N/A

External

Drugs.com

Clinical alerts

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Selectively inhibits CDK4/6, blocking retinoblastoma protein phosphorylation

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Metastatic Breast Cancer
·Advanced Breast Cancer
·Advanced Breast Carcinoma
·Hormone Receptor Positive Breast Carcinoma
·Anatomic Stage II Breast Cancer AJCC v8

Interactions

No curated interaction pairs are recorded for Ribociclib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Neutropenia
Nausea
Fatigue
Diarrhea
QT prolongation

Food, alcohol & herbal

Alcohol · moderate

Additive hepatotoxicity

Pharmacokinetics

Half-life: 33 hours
Protein binding: 70%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Ribociclib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement